

This comment is not totally rigorous. The Spanish Real Academia dictionary ([www.rae.es](http://www.rae.es)) shows two clearly distinct definitions that I have translated: “(1) glass (*vidrio*), (from Latin *vitrum*): solid, fragile material, transparent, without crystalline structure [...]; (2) crystal (*crystal*), (from Latin *crystallus*): solid material whose atoms and molecules are regularly and repeatedly distributed in space.”

However, it is true that in Spain we use the word *crystal* for both concepts in colloquial terms.

**Bruno Contreras Moreira**

*Biomolecular Modelling Laboratory,  
Cancer Research UK, 44 Lincoln's Inn Fields,  
London WC2A 3PX, UK*

*Gautam R. Desiraju replies* — The word *crystal* is most commonly used in Spanish to describe crystal and glass, unlike the English language, where ‘crystal’ refers only to high-quality glass, cut glass and so on. The word *vidrio* is not used so frequently.

### Online comment could promote unfair criticism

*Sir* — David M. Eagleman and Alex O. Holcombe in their Correspondence “Improving science through online commentary” (*Nature* **423**, 15; 2003) have proposed a web-based public arena for post-publication comment on scientific papers. Although we share these authors’ concern that the slowness of peer-reviewed publication holds up comment and rapid (or even any) transmission of corrections, thereby impeding scientific progress, we believe that their proposed solution, a direct link between a website and PubMed entries, itself suffers from difficulties.

Perhaps the most worrisome issue is the likely prevalence of axe-grinding and hidden vested interests on a notice board that is meant for posting logical flaws, experimental weaknesses, questionable assumptions, alternative explanations and even non-replications. Although the proposed moderator could perhaps filter out overtly hostile or libellous notes, it is hard to imagine that he or she would be able to evaluate data adduced as evidence of non-replication.

The idea of post-hoc review is a good one, but Eagleman and Holcombe’s proposed model amounts to a free-for-all, which might encourage ill-considered comment with the potential for damaging worthy science and scientists. One alternative is to provide independent scientific assessment of published papers directly linked to PubMed, as in a

subscription service in which we participate (see [www.facultyof1000.com](http://www.facultyof1000.com)).

**Andrew Lumsden\***, **Martin Raff†**,

**Joshua R. Sanes‡**

*\*MRC Centre for Developmental Neurobiology,  
King's College London, Guy's Hospital,  
London SE1 1UL, UK*

*†MRC Laboratory for Molecular Cell Biology and  
Cell Biology Unit, University College London,  
London WC1E 6BT, UK*

*‡Department of Anatomy and Neurobiology,  
Washington University Medical Center,  
St Louis, Missouri 63110, USA*

### MRC planning outweighs excellence in science

*Sir* — The comprehensive and harsh criticism of the UK Medical Research Council (MRC) by the House of Commons Select Committee for Science and Technology (see *Nature* **422**, 461 and **422**, 545; 2003) has been considered excessive by some but in my opinion is welcome: British science has found a friend. However, in view of the fact that the MRC supports about half the biomedical research in the United Kingdom, I am surprised that there has been no subsequent debate in *Nature* or the UK national press.

The select committee criticizes the MRC’s practice of funding super-large research centres, long-running cooperative grants and interdisciplinary research groups, which leaves almost no funds for independent and young scientists. Closing or downsizing already existing centres with a reputation (such as the MRC’s National Institute for Medical Research: see *Nature* **422**, 545 and **423**, 573; 2003) to free funds for a new one is even more puzzling.

I would like to give my own view on some of the MRC’s problems. First, timing is crucial: creating a huge centre before the people who will run it are identified has risks. If the centre does not work, it is likely that its leader will retire before this becomes evident, and others will be blamed for the failure. In the meantime, other scientists will be deprived of funding.

George Radda, the MRC’s current chief executive, says that if there had been no far-reaching goals 50 years ago, the double-helix structure of DNA would not have been solved. But this advance, as well as the solution of the first protein structures and protein sequencing, were made possible by three visionaries: John Bernal, Lawrence Bragg and John Randall. They had gathered the right people for the tasks and were powerful enough to obtain money from anywhere. The MRC deserves credit for funding these projects, but it did not hurry to create a new huge and expensive research centre in order to do so.

The MRC Laboratory of Molecular Biology (LMB) in Cambridge was created more than ten years later, after six Nobel prizes were awarded and the seventh was in the pipeline. At that time, the MRC recognized that there was already a critical mass of scientists with proven abilities and that funding such a large institution would repay the investment. They were right: the LMB kept attracting more able scientists and several more Nobel prizes were won subsequently.

My second concern is how and why the system of awarding the remaining scarce money for grants was changed. Peer-review assessment is fundamental to the funding of science. In the past, project proposals were assessed by three to four referees, chosen by the relevant MRC committee. Now, proposals are sent to 24 referees and judged when about eight have replied. It is hard to imagine that they would all be well-informed (in my field, there are not 24 centres anywhere that are actively involved in research). Thus, referees are chosen by administrators, who do not have a broad view on who is competent to judge a project, instead of being chosen by practising scientists. The power has shifted from scientists to administrators.

My third concern is the system of marking of the projects: alpha (recommended for funding), beta (with reservations) and gamma (failed). The alpha projects are additionally subdivided, the highest being alpha-A. Many projects are marked alpha-A, several times more than there is money to fund. They cannot all be equally good, but because they all have the same mark, the committee is given the power to choose which grants to support on political or ‘strategic’ grounds, independent of merit. Moreover, ‘strategic’ funding can prejudice the chances of other, perhaps better, projects, as the MRC will consider that it already supports work in that field and that it prefers to shift funds to another field in the strategic plan.

**Dontcho Staynov**

*Department of Asthma, Allergy and Respiratory  
Science, 5th Floor, Thomas Guy House, Guy's  
Hospital, London SE1 9RT, UK*

### Fiendishly clever?

*Sir* — Given the long regard in which lawyers are commonly held, was it just coincidence that led to your Special Report on scientists retraining for the legal profession appearing on page 666 (*Nature* **423**, 666–667; 2003)?

**Rupert C. Marshall**

*School of Biological Sciences, Royal Holloway,  
University of London, Egham,  
Surrey TW20 0EX, UK*